TEST:

Prolaris® + AI

Prolaris will be the first and only prostate cancer biomarker test to unite clinical-pathological features, an independent molecular score, and independent AI-powered digital pathology technology. This combination helps identify if a patient is safe for active surveillance (AS) and how refinement of AS intensity can be personalized. This new paradigm in patient care builds upon technology from PATHOMIQ AI, a digital pathology AI platform company. The Prolaris + AI test is the only test where AS metrics on patient results were built on studies with previously diagnosed, untreated patient cohorts. The Prolaris + AI test will continue to help doctors identify patients who are safe for single-modal treatment